Skip to main content
Equibles

SENORES · Senores Pharmaceuticals Limited · Documents

Use SENORES with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SENORES.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,174.70 INR -41.10 (-3.38%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 16.38K Avg daily vol (3M) 23.3K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Oct 29, 2026
2026
Oct 29
Earnings call
Record Q2 FY27 revenue, FY27 guidance maintained

Senores Pharmaceuticals Limited reported record Q2 FY27 revenue of INR192 crores, up 25% Y-o-Y, with EBITDA at INR58 crores and PAT around INR36.6 crores. Management maintained FY27 guidance for 30% to 40% revenue growth and 50% to 60% PAT growth.

3 source passages
the consolidated revenue from operations for Q2 FY27 stood at INR192 crores, which as Swapnil said is the highest for us, reflecting a very healthy growth of 25% Y-o-Y. Consolidated EBITDA for Q2 2027 stood at INR58 crores, growing by 38% Y-o-Y and EBITDA margin stood at 30%, which improved by 290 bps year-on-year. Profit after tax for the quarter grew by 22% Y-o-Y and came to around INR36.6 crores. we remain on track to achieve our FY27 guidance of 30% to 40% revenue growth and corresponding 50% to 60% PAT growth. Open the document at this passage
Showing 1–3 of 3 documents